鼻咽癌细胞组织与血液的SERS光谱研究进展

基于表面增强拉曼光谱(SERS)技术对于人体细胞组织与血液的检测和研究,SERS光谱技术能够发现正常组织与病变组织的差异性,为医学临床上实现癌症的早期诊断提供了科学依据。由于鼻咽癌不具有明显的病变特征、病灶的位置难以通过常规医学手段检测。因此利用SERS光谱技术,应用于鼻咽癌细胞组织与血液的研究,可提高鼻咽癌患者的生存率。对鼻咽癌细胞组织与血液SERS光谱分析和诊断的探索研究,有助于SERS光谱技术发展成为一种在生物医学领域中的分析检测手段,在医学临床诊断上具有潜在的应用前景。     

拉曼光谱技术在癌症诊断中的研究探讨

拉曼光谱是一种散射光谱,是分析分子结构的常用工具,其在癌症诊断中具有重要的临床意义。本文主要针对拉曼光谱技术在癌症诊断中的应用进行研究和探讨。     

唇腺炎性病变组织的共聚焦显微拉曼光谱特征研究

目的:研究唇腺炎性病变组织的拉曼光谱指纹特征,为拉曼光谱技术临床鉴别诊断唇腺炎性病变提供理论基础。方法:收集舍格伦综合征病变唇腺30例、唇腺急性炎症组织18例及正常唇腺组织30例,应用激光共聚焦显微拉曼光谱仪对唇腺组织进行拉曼光谱检测。应用主成分分析法(Principal component analysis,PCA)及判别函数(Discrimination function analysis,DFA)对光谱数据进行分析,研究唇腺组织光谱指纹诊断价值。结果:唇腺炎症组织与正常组织光谱间存在光谱指纹差异,这些差异代表了某些蛋白、核酸及脂类物质等生物大分子发生改变。PCA-DFA分析发现这些差异性拉曼光谱具有鉴别诊断价值,可以区分不同唇腺组织,总体诊断准确率达91.8%,经交互验证后准确率为89.4%。结论:不同唇腺炎症组织及正常组织间拉曼光谱存在差异,不仅揭示生物大分子改变,还具有临床鉴别诊断价值。拉曼光谱技术在唇腺炎性病变组织鉴别诊断具有巨大应用潜力。     

拉曼光谱在胃癌诊断中的应用与研究进展

拉曼光谱是一种分子振动光谱技术,具有分子水平的肿瘤检测和诊断能力.胃癌是常见恶性肿瘤,经常到晚期才得到诊断,死亡率较高,而早期胃癌预后较好,因此胃癌早期检测和诊断显得尤为重要.文章介绍了拉曼光谱用于胃癌早期检测和诊断的应用,并综述其研究进展,结果认为拉曼光谱探针与内镜整合,将实现胃癌活体检测和诊断,极具临床应用价值.     

功能红细胞研究的拉曼光谱技术与进展

红细胞在人体新陈代谢和物质运输方面起着非常重要的作用。作为一种无损、快速而灵敏的光谱学检测方法,拉曼光谱技术在生物医学领域的应用日渐广泛。本文综述了近年来拉曼光谱技术在红细胞及血红蛋白研究中的应用进展,详尽评述当前研究功能红细胞中较有优势的拉曼技术—显微拉曼光谱技术和光镊拉曼光谱技术,并对其技术的改进做出总结,以期为利用激光拉曼光谱研究红细胞提供较系统的参考。     

结直肠癌早期诊断的研究进展

结直肠癌(colorectal cancer,CRC)的早期诊断对减少肿瘤发病率和死亡率具有极其重要的意义。随着分子生物、内镜影像技术以及激光技术的发展,各种诊断方法不断改进,新诊断方法和技术不断涌现,对结直肠癌的早期诊断、定位和分期提高到了一个新的认知水平。本文简述了结直肠组织的层微结构和癌变进程,介绍了目前临床诊断的主要方法,展望了其发展方向。论文在重点评述非线性光谱技术,包括双光子激发荧光、二次谐波以及拉曼光谱在CRC诊断研究的基础上,提出联合多光子显微成像与拉曼光谱技术进一步开展结直肠癌早期无损诊断研究。     

拉曼光谱检测微生物的研究方法和进展北大核心

快速准确地识别和鉴定微生物对于环境科、食品质量以及医学诊断等领域研究至关重要。拉曼光谱(Raman spectroscopy)已经被证明是一种能够实现微生物快速诊断的新技术,在提供微生物指纹图谱信息的同时,能够快速、非标记、无创、敏感地在固体和液体环境中实现微生物单细胞水平的检测。本文简单介绍了拉曼光谱的基本概念和原理,重点综述了拉曼光谱微生物检测应用中的样品处理方法及光谱数据处理方法。除此之外,本文概括了拉曼光谱在细菌、病毒和真菌中的应用,其中单独概括了拉曼在细菌快速鉴定和抗生素药敏检测中的应用。最后,本文阐述了拉曼光谱在微生物检测中的挑战和展望。     

拉曼光谱检测胃癌变信号的研究

利用激光拉曼光谱对胃癌患者血清及非胃癌患者血清进行对比检测,并结合对体外培养胃癌细胞分泌物的检测,对胃癌特征拉曼峰作初步探讨。得出一种有重要临床应用价值的癌症辅助快速诊断方法。     

拉曼光谱技术在微生物学中的应用

拉曼光谱具有快速、灵敏、无损、实时监测等显著特点,在微生物学领域得到广泛应用。分别介绍共焦显微拉曼光谱、共振拉曼光谱、表面增强拉曼光谱、拉曼成像、相干反斯托克斯拉曼光谱、激光镊子拉曼光谱和Raman-FISH的原理和特点,并重点总结和分析不同拉曼光谱技术在微生物的结构、化学组成,以及代谢过程等相关研究中的应用优势。合理利用这些技术在基础微生物、发酵微生物和微生物诊断等方面具有潜在的应用价值。     

激光技术在农产品质量检测中的研究进展

近年来激光在农业领域得到广泛的应用和研究,其中的一个最新进展是将激光技术应用于农产品内部品质和安全性检测。本文介绍了农产品质量检测中的几种激光技术,包括应用激光的吸收与反射技术来检测农产品糖酸度、质地、PH值、成熟度、干物质等;应用激光诱导荧光技术来检测农产品的农药残留、叶绿素、成熟度;应用激光拉曼光谱技术来检测农产品水果损伤、农药残留。对农产品激光检测的未来发展趋势进行了探讨和展望。     

Direct observation of spectral differences between normal and basal cell carcinoma (BCC) tissues using confocal Raman microscopy

Raman spectroscopy has strong potential for providing noninvasive dermatological diagnosis of skin cancer. In this study, confocal Raman microscopy was applied to the dermatological diagnosis for one of the most common skin cancers, basal cell carcinoma (BCC). BCC tissues were obtained from 10 BCC patients using a routine biopsy and used for confocal Raman measurements. Autofluorescence signals from tissues, which interfere with the Raman signals, were greatly reduced using a confocal slit adjustment. Distinct Raman band differences between normal and BCC tissues for the amide I mode and the PO2- symmetric stretching mode showed that this technique has strong potential for use as a dermatological diagnostic tool without the need for statistical treatment of spectral data. It was also possible to precisely differentiate BCC tissue from surrounding noncancerous tissue using the confocal Raman depth profiling technique. We propose that confocal Raman microscopy provides a novel method for dermatological diagnosis since direct observations of spectral differences between normal and BCC tissues are possible.     

表面增强拉曼散射技术无标记检测乳腺癌细胞来源外泌体

外泌体含有释放细胞的特异性物质,反映了释放细胞的组成成分,成为液体活检的重要物质。为了鉴别正常乳腺上皮细胞和乳腺癌细胞来源的外泌体,本研究采用表面增强拉曼(SERS)技术检测乳腺癌细胞MCF-7和人正常乳腺上皮细胞MCF-10A来源的外泌体,并且对比两种细胞外泌体的SERS光谱,筛选出相应的特征拉曼光谱。结果发现在800~1800 cm-1区域内,相对MCF-10A细胞,MCF-7来源的外泌体中归属于核酸的拉曼峰相对强度明显增高,且部分脂类峰强有所降低或部分特征峰消失,同时发现MCF-7还表现出其自己独特的拉曼谱型。此结果表明SERS技术可高灵敏度检测不同细胞来源的外泌体细微分子变化,可区分肿瘤细胞来源的外泌体与正常细胞来源的外泌体。SERS技术可作为癌症的早期检测和诊断的一种快速、无标记和无损的方法。     

Optical diagnosis of laryngeal cancer using high wavenumber Raman spectroscopy

We report the implementation of the transnasal image-guided high wavenumber (HW) Raman spectroscopy to differentiate tumor from normal laryngeal tissue at endoscopy. A rapid-acquisition Raman spectroscopy system coupled with a miniaturized fiber-optic Raman probe was utilized to realize real-time HW Raman (2800-3020 cm(-1)) measurements in the larynx. A total of 94 HW Raman spectra (22 normal sites, 72 tumor sites) were acquired from 39 patients who underwent laryngoscopic screening. Significant differences in Raman intensities of prominent Raman bands at 2845, 2880 and 2920 cm(-1) (CH(2) stretching of lipids), and 2940 cm(-1) (CH(3) stretching of proteins) were observed between normal and cancer laryngeal tissue. The diagnostic algorithms based on principal components analysis (PCA) and linear discriminant analysis (LDA) together with the leave-one subject-out, cross-validation method on HW Raman spectra yielded a diagnostic sensitivity of 90.3% (65/72) and specificity of 90.9% (20/22) for laryngeal cancer identification. This study demonstrates that HW Raman spectroscopy has the potential for the noninvasive, real-time diagnosis and detection of laryngeal cancer at the molecular level.     

拉曼光谱在皮肤领域的研究进展

拉曼光谱是一种新型的光学检测技术,常用于材料鉴定。近年来,随着无创检测需求的增加,拉曼光谱逐渐应用于疾病诊断、物质鉴别等生物领域。综述了拉曼光谱在皮肤领域的研究进展,及其对皮肤组织成分鉴别和皮肤疾病诊断的价值,以期推动拉曼光谱广泛应用于皮肤病学的机理研究和临床诊断。     

Biomarkers in molecular medicine: cancer detection and diagnosis

In spite of advances in diagnostics and therapeutics, cancer remains the second leading cause of death in the U.S. Successful cancer treatment depends not only on better therapies but also on improved methods to assess an individual's risk of developing cancer and to detect cancers at early stages when they can be more effectively treated. Current cancer diagnostic imaging methods are labor-intensive and expensive, especially for screening large asymptomatic populations. Effective screening strategies depend on methods that are noninvasive and detect cancers in their early stages of development. There is increasing interest and enthusiasm in molecular markers as tools for cancer detection and prognosis. It is hoped that newly discovered cancer biomarkers and advances in high-throughput technologies would revolutionize cancer therapies by improving cancer risk assessment, early detection, diagnosis, prognosis, and monitoring therapeutic response. These biomarkers will be used either as stand-alone tests or to complement existing imaging methods.     

Integrated photoacoustic and hyperspectral dual‐modality microscopy for co‐imaging of melanoma and cutaneous squamous cell carcinoma in vivo

Skin carcinoma such as melanoma (MM) and cutaneous squamous cell carcinoma (cSCC) are considered as the highest mortality and the most aggressive skin cancers in dermatology. In view that early diagnosis and treatment can greatly improve the survival rate and life quality of the patients, developing noninvasive and effective evaluation methods is of great significance for the detection and identification of early stage cutaneous cancers. In this article, we propose a hybrid photoacoustic and hyperspectral dual‐modality microscopy to evaluate and differentiate skin carcinoma by structural and multiphysiological parameters. The proposed system's imaging abilities are verified by mimic phantoms and normal mice experiments. Furthermore, in vivo characterization and evaluation results of MM and cSCC mice are obtained successfully, which prove this novel method could be used as a reliable and useful method for skin cancer detection in early stages.     

Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers

Cancer is considered as a challenging lethal agent around the world and its detection at early stages would help prevention of the high mortality. Among the widely used biomarkers in clinical diagnosis of cancer, extracellular non-coding RNAs as ribonucleic acid biomarkers serve as state-of-the-art candidates for molecular diagnosis. In that regard, microRNAs are of great priority mainly because of high variety and stability in body fluids. Accordingly, common miRNAs among most prevalent cancers could help us (pre)diagnose cancer with high accuracy in target samples. In this study, common lethal cancers to humans were investigated in case of miRNA profiles to determine the possible common correlation between miRNA up-regulation or down-regulation (as a ribonucleic acid biomarker) and developing the cancers. It was shown that among the investigated miRNAs, five typical extracellular miRNAs (miR-18a, miR-21, miR-155, miR-221, and miR-375) dysregulation are predominant in most cancer varieties comprising breast, colon, lung, prostate, pancreas, gastric, ovarian, esophagus and liver. This could serve as an appropriate target site for developing point-of-care approaches for cancer detection e.g. designing diagnostic biosensor-based microarrays or kits for both quantification and qualification of the biomarkers. Besides, the miRNA candidates could be efficiently applied to cancer therapeutic approaches.     

粪便RNA的检测在大肠癌早期诊断中的应用

大肠癌是胃肠道恶性肿瘤之一,在我国大肠癌的发病率和死亡率呈上升趋势。由于死亡率与大肠癌的诊断时间密切相关,因此早期诊断大肠癌尤为重要。但是目前临床常规诊断方法存在一定的局限性,难以实现大肠癌的早期诊断。粪便RNA检测技术是近年来发展的基于分子水平的早期无创检测大肠癌的技术,与常规检测技术包括结肠镜检测、大便隐血检测和粪便DNA突变检测相比,粪便RNA检测具有成本低和灵敏度高等优点,并可同时分析多种基因表达量和动态监测肿瘤进展。文章介绍了粪便RNA检测的可行性,系统阐述了用于粪便RNA检测的特异性基因、粪便RNA的提取方法和粪便RNA的检测技术,并对粪便RNA检测技术在大肠癌早期诊断中的进一步应用进行了展望。     

Proteomics of breast carcinoma

Beast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The advent of proteomics provides the hope of discovering novel biological markers that can be used for early detection, disease diagnosis, prognostication and prediction of response to therapy. Several proteomics technologies including 2D-PAGE, 2D-DIGE, ICAT, SELDI-TOF, MudPIT and protein arrays have been used to uncover molecular mechanisms associated with breast carcinoma at the global level, and a number of these technologies, particularly the SELDI-TOF hold promise as a proteomic approach that can be applied at the bedside for discovering protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Laser microdissection, a method for selection of homogenous cell populations, coupled to 2D-DIGE or MudPIT constitute a new proteomics-based paradigm for detecting disease in pathology specimens and monitoring disease response to therapy. This review describes proteomics technologies, and their application in the proteomic analysis of breast carcinoma.     

Surface-enhanced Raman scattering detection of wild-type and mutant p53 proteins at very low concentration in human serum

The development of ultrasensitive and rapid approaches to detect tumor markers at very low concentrations even in a physiological environment represents a challenge in nano-medicine. The p53 protein is at the center of the cellular network that protects organisms against the insurgence of tumors, most of which are related to alteration of p53 expression. Therefore p53 is regarded as a valuable prognostic marker whose detection at high sensitivity may considerably contribute to early diagnosis of cancers. In this work we have applied an analytical method based on surface enhanced Raman spectroscopy with high sensitivity and rapidity to improve traditional bioaffinity techniques. The Raman reporter bifunctional linker 4-aminothiophenol (4-ATP) first assembled onto 50 nm gold nanoparticles (Nps) has then been azotated to bind low concentration wild-type and two mutated forms of p53 proteins. The Raman signal enhancement of the resulting p53-(4-ATP-Np) systems has been used to identify the p53 molecules captured on a recognition substrate constituted by the azurin (Az) protein monolayer. Az has shown a strong association for both wild-type and mutated p53 proteins, allowing us to selectively detect these proteins at concentrations as low as 500 fM, in a human serum environment.